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Abstract
Background: This systematic review evaluated St. John’s wort (SJW) for the treatment of Major Depressive Disorder
(MDD). The objectives of this review are to (1) evaluate the efficacy and safety of SJW in adults with MDD
compared to placebo and active comparator and (2) evaluate whether the effects vary by severity of MDD.
Methods: We searched PubMed, CINAHL, PsycINFO, CENTRAL, Embase, AMED, MANTIS, Web of Science, and ICTRP
and existing reviews to November 2014. Two independent reviewers screened the citations, abstracted the data,
and assessed the risk of bias. We included randomized controlled trials (RCTs) examining the effect of at least a 4-
week administration of SJW on depression outcomes against placebo or active comparator in adults with MDD. Risk
of bias was assessed using the Cochrane Risk of Bias tool and USPSTF criteria. Quality of evidence (QoE) was
assessed using the GRADE approach.
Results: Thirty-five studies examining 6993 patients met inclusion criteria; eight studies evaluated a hypericum extract
that combined 0.3 % hypericin and 1–4 % hyperforin. The herb SJW was associated with more treatment responders
than placebo (relative risk [RR] 1.53; 95 % confidence interval [CI] 1.19, 1.97; I2 79 %; 18 RCTs; N = 2922, moderate QoE;
standardized mean differences [SMD] 0.49; CI 0.23, 0.74; 16 RCTs; I2 89 %, N = 2888, moderate QoE). Compared to
antidepressants, SJW participants were less likely to experience adverse events (OR 0.67; CI 0.56, 0.81; 11 RCTs;
moderate QoE) with no difference in treatment effectiveness (RR 1.01; CI 0.90, 1.14; 17 RCTs, I2 52 %, moderate QoE;
SMD −0.03; CI −0.21, 0.15; 14 RCTs; I2 74 %; N = 2248, moderate QoE) in mild and moderate depression.
Conclusions: SJW monotherapy for mild and moderate depression is superior to placebo in improving depression
symptoms and not significantly different from antidepressant medication. However, evidence of heterogeneity and a
lack of research on severe depression reduce the quality of the evidence. Adverse events reported in RCTs were
comparable to placebo and fewer compared with antidepressants. However, assessments were limited due to poor
reporting of adverse events and studies were not designed to assess rare events. Consequently, the findings should be
interpreted with caution.
Systematic review registration: PROSPERO CRD42015016406.
Keywords: St. John’s wort, Major depressive disorder, Complementary and alternative medicine, Herb, Systematic
review, Meta-analysis, Antidepressant
Abbreviations: AMED, Allied and Complementary Medicine Database; CENTRAL, Cochrane Central Register of
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Background
Depressive disorders are one of the largest sources of
disease burden. More than 350 million people worldwide
suffer from depression at any one time, and this number
appears to be on the rise [1]. The condition affected ap-
proximately 15 million individuals in the USA in the last
year, with a 12-month prevalence of 4.8 % in men and
8.2 % in women, yet the condition remains underdiag-
nosed and undertreated [2]. Depression has severe con-
sequences for the lives of individuals. Nearly 43 % of
those with severe depression in the USA report serious
difficulties with work, home, or social activities [3]. De-
pression is also linked to an estimated productivity loss
of 5.6 h per week and $40 billion a year [4].
Pharmacotherapy and psychotherapy are established
treatments and have been shown to be effective to treat
depressive disorders, such as major depressive disorder
(MDD). However, stigma, costs, discomfort with, or lack
of availability of, mental health treatment, side effects of
medication, and other factors cause many individuals to
not seek standard treatments. For centuries, extracts of
the herb St. John’s wort (botanical name Hypericum per-
foratum L., SJW) have been used to treat various condi-
tions, including depressive disorders. Existing clinical
practice guidelines vary in their recommendations to in-
clude SJW as a treatment option for treating depressive
disorders [5]. A Cochrane Review of SJW for depression
documented available research studies published to 2008
and found a beneficial effect compared to both placebo
and other antidepressant therapies across 29 double-
blind randomized controlled trials (RCTs) [6]. The re-
view concluded that the available evidence suggested
that hypericum extracts tested in the included trials are
superior to placebo and patients with major depression
and are similarly effective as standard antidepressants,
and have fewer side effects than standard antidepres-
sants. Overall, SJW has been considered safe but side ef-
fects have been noted, including photosensitivity,
elevated thyroid stimulating hormones, hypertensive cri-
sis, and induction of mania [7]. In addition, preparations
of SJW vary in the amounts of active compounds they
contain, which may make it difficult to compare across
studies [8].
In recent years, more research on SJW has been pub-
lished in the international literature testing not only its
effectiveness compared to placebo conditions but testing
also its comparative effectiveness and comparative safety
compared with standard antidepressant treatment. This
review aims to synthesize all available RCTs in a com-
prehensive systematic review in order to provide reliable
and current estimates of the effectiveness and compara-
tive effectiveness and safety of SJW compared to placebo
or antidepressant treatment in the treatment of adults
with MDD (see Additional file 1 for PRISMA checklist).
We set out to answer the following review questions:
 What are the efficacy and safety of SJW in adults
with MDD compared to placebo and active
comparator?
 Is there a difference in effect, depending on the type
of MDD (i.e., mild, moderate, severe)?
Methods
Search strategy
We searched the electronic databases PubMed, CINAHL
(Cumulative Index to Nursing and Allied Health Litera-
ture), PsycINFO, CENTRAL (Cochrane Central Register
of Controlled Trials), Embase, AMED (Allied and Com-
plementary Health Database), MANTIS (Manual, Alter-
native, and Natural Therapy Index System), Web of
Science, and ICTRP (International Clinical Trials Regis-
try Platform) without language restriction from January
2007 to November 2014 to identify recent reports of
RCTs testing the efficacy and safety of SJW—used
adjunctively or as monotherapy—to treat adults with
MDD. RCTs published earlier than 2007 were identified
through reference mining of included studies and previ-
ous systematic reviews related to SJW, including a
Cochrane review that included trials on SJW for MDD
published to July 2007 [6]. The Cochrane review con-
ducted a comprehensive search to locate SJW RCTs in
the Clinical Trials Register of the Cochrane Collabor-
ation Depression Anxiety & Neurosis Group
(CCDANTR) until 2007, in PubMed until 2008, in the
database of the Cochrane Field for Complementary
Medicine, in the Medline SilverPlatter CD-ROM from
1983 onwards, in Embase from 1989 onward, in the Psy-
chlit and Psychindex 1987–1997 CD-ROM, and in Phy-
todok [6]. We screened all studies identified in the
systematic searches, i.e., studies included or excluded
from the Cochrane review. All studies included in the
2008 Cochrane review were eligible for inclusion, but
our review also identified head-to-head trials comparing
different St. John’s wort extracts, different dosage, and
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standard antidepressant interventions (including psycho-
therapy). Our search was not limited to peer-reviewed lit-
erature; we included grey literature, such as conference
abstracts. We contacted authors to obtain full-text publi-
cations cited in other reviews or indexed in databases that
were not available through information retrieval services
or the original publisher; but, due to resource restrains,
we did not systematically contact all authors for potential
additional studies or data. The search strategy is available
online. (see Additional file 2).
Eligibility criteria
The inclusion and exclusion criteria for this review were
developed using the framework of participants, interven-
tions, comparators, outcomes, timing, settings, and
study design or PICOTSS:
 Participants: Studies in adults, male and female,
18 years of age and over, with a diagnosis of MDD
were eligible for inclusion in the review. In studies
not referring to a clinical diagnosis based on
Diagnostic and Statistical Manual of Mental
Disorders (DSM) or International Classification of
Diseases (ICD) criteria, we applied a specified
threshold on validated depression scales (see
Additional file 3). Studies that enrolled individuals
with other comorbid conditions, such as traumatic
brain injury, were eligible for inclusion. Studies in
participants in postnatal depression were included if
the criteria were in accordance with DSM-V criteria
for MDD (i.e., peripartum onset or 4 weeks follow-
ing delivery). Studies in individuals with diagnoses of
dysthymia, bipolar disorder, or schizophrenia, alone
or in combination with major depression, were ex-
cluded in accordance with DSM-V criteria. Studies
evaluating multiple psychiatric conditions were in-
cluded if the data for patients with MDD were pre-
sented separately.
 Interventions: Studies that administered a
supplement that contained a known amount of SJW,
and the amount and type of active compounds
contained in the SJW supplement that was specified
(i.e., naphthodianthrones, hypericin,
pseudohypericin, flavonoids, phloroglucinols,
hyperforin, and adhyperforin), were eligible. SJW
could be evaluated alone or in conjunction with
pharmacologic and/or psychotherapy.
 Comparator: Studies comparing SJW with placebo
or with active comparators, or against another
amount or extract of SJW, were eligible.
 Outcomes: Studies that reported Hamilton clinical
rating scale for depression (HAMD) scores or other
validated depression scale scores were eligible for
inclusion as well as studies that reported other
changes in depressive symptoms (e.g., suicidal
ideation) or the rate of treatment responders.
Studies that reported the number of patients in
remission or rates of depression relapse were also
eligible. Studies that reported adverse events in
adults taking SJW for MDD were included if adverse
events were reported by study arm. Studies that
reported on biomarkers alone without reporting
efficacy for depression outcomes were excluded.
Only studies that at least reported outcome
assessments at baseline and at the end of treatment
for both study arms were included. Studies of
healthcare provider outcomes, acceptance,
prevalence, use, costs, study design features, and
intervention features not reporting patient health
outcomes were excluded.
 Timing: Only studies with a treatment duration of
4 weeks or longer were eligible.
 Setting: Studies were not limited by setting (e.g.,
country, physical location of treatment).
 Study design: Included studies were limited to RCTs.
Inclusion screening
All article screening and abstraction was conducted using
the systematic review software DistillerSR (Evidence Part-
ners, Ottawa, Canada). Two independent reviewers
screened titles and abstracts of retrieved citations. Cita-
tions judged as potentially eligible by one or both re-
viewers were obtained as full text. The full-text
publications were screened against the specified inclusion
criteria by the two independent reviewers using a stan-
dardized and pilot-tested form; any disagreements were
resolved through discussion within the review team.
Studies reporting on the same participants were
counted as one study regardless of the number of publi-
cations the results were presented in. All study-related
publications were considered and contributed to the
data extraction.
Data extraction
Two reviewers abstracted study-level information. Cat-
egorical data concerning study details were abstracted
independently by both reviewers; free text information
concerning study details were abstracted by one reviewer
and checked by the review lead. The reviewers pilot-
tested the data collection forms prior to data extraction
to ensure agreement of interpretation. Numerical out-
come data were abstracted and checked by a single
biostatistician.
The following information was abstracted from each
study:
 Participants: MDD diagnostic criteria, baseline
measure of depression symptoms, depression
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severity (mild, moderate, or severe) using the
authors’ description, depression history (e.g.,
recurrent), comorbidities, mean age and age range,
gender
 Interventions: details including amount and type of
active compounds contained in the SJW
supplement, dosage, co-intervention(s)
 Comparators: type and description of comparator
 Outcomes assessed: assessment measures and
primary endpoint, method of data expression (e.g.,
mean difference), results (effect estimate, precision)
 Timing: time-points of outcome assessment, dur-
ation of intervention
 Setting: country
 Study design: aim of study, inclusion and exclusion
criteria, sample size and reported power
calculations, funding source.
Outcome data were based on intention-to-treat (ITT)
analyses. In the absence of reported ITT data, we used
the number randomized as the denominator; in the ab-
sence of the number randomized, we used the number
of participants at follow-up. All studies were analyzed
using the latest reported follow-up; however, studies
reporting follow-up only for a subsample of treatment
responders were not considered. Follow-up used the
baseline as the point of reference, not the end of treat-
ment; most studies assessed treatment effects directly
after the end of treatment but treatment duration varied.
When multiple depression measures were available, we
used HAMD scores to assess treatment effects on de-
pression symptoms. We used the authors’ definition of
response to treatment, usually reflecting a 50 % decrease
in HAMD scores. We used the authors’ definition of re-
mission, usually reflecting a HAMD score of less than
seven or eight. We computed standardized mean differ-
ences (SMDs) for studies reporting continuous out-
comes, relative risks (RRs) for treatment effect estimates,
and odds ratios (ORs) for rare adverse events, together
with the 95 % confidence interval (CI).
Risk of bias
Two reviewers independently assessed the risk of bias of
included studies using the Cochrane Risk of Bias tool [9]
and criteria used by the US Preventative Services Task
Force [10]. We assessed random sequence generation
(selection bias); allocation concealment (selection bias);
blinding of participants and providers (performance
bias); blinding of outcome assessors (detection bias);
completeness of reporting outcome data (attrition bias);
selective outcome reporting (reporting bias); whether
treatment group received plus treatment as usual SJW
and the control group received treatment as usual plus
no additional treatment (“add-on trial”); washout periods
or exclusion of individuals taking personal supplement;
equal distribution among groups of potential con-
founders at baseline; crossovers or contamination be-
tween groups; equal, reliable, and valid outcome
measurement; clear definitions of interventions; and ITT
analysis. The criteria were used to rate the quality of in-
dividual studies using the following guidelines [10, 11]:
 Good: Comparable groups are initially assembled
and maintained throughout the study with at least
80 % follow-up; reliable, valid measurement is used
and applied equally to all groups; interventions are
clearly described; all important outcomes are consid-
ered; appropriate attention is given to confounders
in analysis; and ITT analysis is used.
 Fair: One or more of the following issues is found in
the study: some though not major differences
between groups exist at follow-up; measurement in-
struments are acceptable but not ideal, though are
generally applied equally; some but not all important
outcomes are considered; some but not all potential
confounders are accounted for in analyses. ITT ana-
lysis must be done.
 Poor: One or more of the following “fatal flaws” is
found in the study: initially assembled groups are
not comparable or maintained throughout the study;
unreliable or invalid measurements are used or
applied unequally across groups; key confounders
are given little to no attention in analyses; ITT
analysis is not used.
Critical appraisal assessments were used for sensitivity
analyses by excluding poor quality studies to evaluate
the robustness of findings.
Data synthesis
The primary aim of this systematic review was to deter-
mine effects of SJW on depressive symptoms, quality of
life, and adverse events compared with placebo and ac-
tive comparators. We differentiated effectiveness and
comparative effectiveness analyses. Placebo trials were
used to estimate the treatment effect of SJW by demon-
strating effects that go beyond placebo effects. A further
key aim of the review was to determine the comparative
effectiveness of SJW compared with standard antidepres-
sant treatment (both psychotherapy or antidepressant
medication). Comparative effectiveness results and
equivalence assessments of the efficacy and safety took
the consistency of effects across individual studies and
the statistical power to detect a statistically significant
difference between treatment groups into account. For
all efficacy outcomes and the number of patients with
adverse events, we used the Hartung-Knapp-Sidik-Jonk-
man method for a random effects meta-analysis [12–14].
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For specific adverse events, many of which are very rare,
we used exact conditional methods to estimate ORs and
CIs. Heterogeneity was assessed using the I2 statistic and
values above 75 % were interpreted as possibly repre-
senting considerable heterogeneity.
We conducted preplanned subgroup analyses for dif-
ferent patient groups depending on the severity of de-
pression. In studies comparing SJW to antidepressant
medication we differentiated selective serotonin reuptake
inhibitors (SSRIs), tricyclic antidepressants (imipramine,
amitriptyline), and other (e.g., maprotiline, Deanxit).
Further meta-regressions were conducted to identify
sources of heterogeneity across studies where appropri-
ate. We conducted sensitivity analyses to test the robust-
ness of results (e.g., to test effects in studies with
sufficient power to detect effect differences between
study arms or excluding poor quality studies). Publica-
tion bias was assessed with the Begg and Egger tests; in
the case of indications for bias, treatment estimates were
estimated using the trim-and-fill method.
Quality of evidence
The quality of evidence was assessed using the GRADE
approach [15]. The body of evidence was evaluated on
the following dimensions: study limitations, inconsist-
ency, directness, and precision. The quality was down-
graded when results were primarily based on studies
with substantial limitations and suspected risk of bias;
when results were inconsistent across individual studies
or the result was based on a single study without replica-
tion in an independent research study; in the presence
of substantial heterogeneity in pooled analyses and vari-
ation in the direction of effects; when conclusions were
based on indirect evidence (e.g., effects bases on sub-
group analyses or meta-regressions in the absence of
head-to-head comparisons); and when pooled results
were imprecise estimates of the treatment effect with
wide confidence intervals spanning effect sizes with dif-
ferent clinical conclusions. The quality of evidence was
graded on a 4-item scale:
 High indicates that review authors are very
confident that the effect estimate lies close to the
true effect for a given outcome, as the body of
evidence has few or no deficiencies. As such, the
reviewers believe the findings are stable and further
research is very unlikely to change confidence in the
effect estimate.
 Moderate indicates that the review authors are
moderately confident that the effect estimate lies
close to the true effect for a given outcome, as the
body of evidence has some deficiencies. As such, the
reviewers believe that the findings are likely to be
stable, but further research may change confidence
in the effect estimate and may even change the
estimate.
 Low indicates that the review authors have limited
confidence that the effect estimate lies close to the
true effect for a given outcome, as the body of
evidence has major or numerous (or both)
deficiencies. As such, the reviewers believe that
additional evidence is needed before concluding
either that the findings are stable or that the effect
estimate lies close to the true effect.
 Very low indicates that the review authors have very
little confidence that the effect estimate lies close to
the true effect for a given outcome, as the body of
evidence has very major deficiencies. As such, the
true effect is likely to be substantially different from
the estimated effect; thus, any estimate of effect is
very uncertain.
This review was registered in PROSPERO
CRD42015016406.
Results
We identified 594 potentially relevant citations through
the electronic database search and reference mining. We
obtained 93 studies as full text. In total, 35 studies met
inclusion criteria (see Fig. 1 for PRISMA diagram)
[16–50]. All studies addressed the efficacy of SJW
reporting on the rate of treatment responders, mean
scores on depression scales, or the number of patients in
remission. Very few studies reported on relapse and
quality of life and studies. In total, 34 studies addressed
safety and reported on the number of patients with ad-
verse events or the frequency of individual events. Risk
of bias in included studies varied: ten studies were rated
“good,” 14 “fair,” and 11 “poor” quality (see Table 1).
Table 2 shows key characteristics of the included studies.
The summary of findings table (Table 3) summarizes
the review findings by comparator and outcome, the
GRADE score, and the reason for downgrading the qual-
ity of evidence, where applicable.
Review question 1: What are the efficacy and safety of
SJW in adults with MDD compared to placebo or
active comparator?
To answer our first research question, we examined
the efficacy and safety of SJW compared to both placebo
and standard antidepressant treatment.
SJW vs. placebo
a. Efficacy. We found evidence that SJW is associated
with statistically significant improvement in depression
symptoms compared to placebo. SJW groups reported
significantly more treatment responders (RR 1.53; CI
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1.19, 1.97; I2 79 %; 18 RCTs; N = 2922; Fig. 2). Partici-
pants receiving SJW also had significantly lower mean de-
pression scale scores (SMD 0.49; CI 0.23, 0.74; 16 RCTs; I2
89 %, N = 2888; Fig. 3) than participants receiving a pla-
cebo. Both analyses indicated substantial heterogeneity
that lowered the quality of evidence. Sensitivity analyses
showed very similar results when excluding poor quality
studies indicating that the effects of SJW were not primar-
ily driven by poor methodological quality.
We found no statistically significant difference in the
number of patients in remission comparing SJW and
placebo (RR 1.69; CI 0.63 to 4.55; 9 RCTs; I2 94 %, N =
1419; Fig. 4). However, there was considerable hetero-
geneity which lowered the quality of evidence assess-
ment and the direction of effects varied across studies:
in the majority favoring SJW but two studies reported
more patients in remission in the placebo arm. Results
were similar when excluding poor quality studies and
between-study heterogeneity was not reduced. In the
majority of studies the number of patients in remission
was small in both treatment arms. The median follow-
up time across studies was 6 weeks (range 4–12 weeks).
Relapse was only assessed in one study without repli-
cation by another study and did not indicate a statisti-
cally significant difference between SJW and placebo.
Quality of life was assessed in two fair quality trials; SJW
treatment effects were shown to be superior for the
mental but not for the physical component (see Table 3).
b. Safety. Most (34/35) of the included studies ad-
dressed the safety of SJW, but rigor of assessment varied
greatly. In the included RCTs, SJW was not more likely
to cause patients to experience adverse events than pla-
cebo overall (OR 0.83; CI 0.62, 1.13; 13 RCTs, Table 3).
The total number of serious adverse events also did not
differ significantly between patients who were adminis-
tered SJW and those who were received a placebo (OR
0.26; CI 0.04, 1.23; 6 RCTs, Table 3).
Targeting specific adverse events by organ system, we
found that adverse events in the neurologic/nervous sys-
tem and various other organ systems (e.g., eye, ear, liver,
renal, reproductive) were more likely in those taking
SJW (OR 1.56; CI 1.08, 3.32; 14 RCTs); all other compar-
isons were not statistically significant (see Table 3).
However, across studies, the adverse event assessments
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Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Low risk NA Low risk Poor
Bernhardt,
1993 [16]
Unclear risk Unclear risk High risk High risk Unclear risk Unclear risk Low risk NA Unclear risk Poor
Bjerkenstedt,
2005 [18]
Unclear risk Unclear risk Low risk Low risk Low risk Unclear risk Low risk NA Low risk Fair
Brenner,
2000 [19]
Unclear risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Fava,
2005 [20]
Unclear risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Poor
Gastpar,
2005 [21]
Low risk Unclear risk Low risk Unclear risk Unclear risk Unclear risk Low risk NA Low risk Poor
Gastpar,
2006 [22]
Low risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
HDTSG,
2002 [23]
Low risk Low risk Low risk Low risk Unclear risk Low risk Low risk NA Low risk Fair
Hangsen,
1994 [48]
Low risk Low risk Low risk Unclear risk Unclear risk Unclear risk Low risk NA Low risk Poor
Harrer,
1993 [24]
Low risk Unclear risk Low risk Unclear risk Unclear risk Unclear risk Low risk NA Low risk Poor
Harrer,
1999 [25]
Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Kalb,
2001 [26]
Low risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
Kasper,
2006 [27]
Low risk Low risk Low risk Low risk Unclear risk Low risk Low risk NA Low risk Fair
Kasper,
2008 [28]
Low risk Low risk Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk Fair
Laakmann,
1998 [29]
Low risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
Lecrubier,
2002 [30]
Unclear risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Lenoir,
1999 [31]
Unclear risk Low risk Unclear risk Unclear risk Unclear risk Unclear risk Low risk NA Low risk Poor
Liu, 2010
[32]













Table 1 Study quality/risk of bias for individual included studies (Continued)
Mannel, 2010
[33]
Low risk Low risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
Montgomery,
2000 [34]
Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Low risk NA Unclear risk Poor
Moreno,
2005 [35]
Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Pakseresht,
2012 [36]
Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Philipp,
1999 [37]
Unclear risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Rahman,
2008 [38]
Low risk Low risk Low risk Unclear risk Unclear risk Unclear risk Low risk NA Low risk Poor
Schrader,
1998 [40]
Low risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
Schrader,
2000 [39]
Unclear risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Shelton,
2001 [41]
Low risk Low risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
Szegedi,
2005 [42]
Low risk Low risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
Uebelhack,
2004 [43]
Low risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
Volz,
2000 [50]
Unclear risk Low risk Low risk Low risk Low risk Unclear risk Low risk NA Low risk Good
Vorbach,
1997 [44]
Low risk Unclear risk Low risk Unclear risk Unclear risk Unclear risk Low risk NA Low risk Poor
Wheatley,
1997 [45]
Low risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Good
Witte.
1995 [49]
Unclear risk Low risk Low risk High risk Low risk Unclear risk Low risk NA Low risk Good
Woelk,
2000 [46]
Low risk Unclear risk Low risk Unclear risk Low risk Unclear risk Low risk NA Low risk Fair
van Gurp,
2002 [47]
Low risk Low risk Low risk Low risk Low risk Unclear risk Low risk NA Low risk Fair













Table 2 Evidence table






Number of participants: 70
Diagnosis: clinical rating scale for depression, MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): 18–73 overall; 51.4 (10.9) SJW; 48.0 (12.6)
fluoxetine, gender (% male): 29 % SJW; 34 % fluoxetine; (1
participant missing from SJW group)
Extract: Hypericum perforatum
Dosage: 150 mg (0.450–0.495 mg total hypericin), 6 weeks
Comparator: fluoxetine





Number of participants: 55
Diagnosis: clinical rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): 54.5 (11.6), gender (% male): 29 %
Extract: hypericin
Dosage: 0.25 mg extract/3 times per day (morning/noon/
night), 4 weeks; Comparator: 0.25 mg extract/3 times per
day (2 in the morning, 1 at noon)





Number of participants: 174
Diagnosis: MDD (DSM), clinical rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): 49.1 (12.0) SJW; 50.4 (11.6) fluoxetine;
51.4 (11.8) placebo; gender (% male): SJW 20 %; fluoxetine
24 %: placebo 18 %
Extract: hypericum LI 160
Dosage: 300 mg, 3 times per day, daily, 4 weeks
Comparator: fluoxetine, placebo





Number of participants: 30
Diagnosis: MDD (DSM) and clinical rating scale for
depression
Severity: mild-moderate
Age (years, M (SD)): 45; gender (% male): 37 %
Extract: LI 160
Dosage: 600 mg per day during week 1, followed by
900 mg per day for the remainder of the trial
Comparator: sertraline





Number of participants: 135
Diagnosis: MDD (DSM), clinical rating scale for depression,
other diagnosis, SCID
Severity: moderate
Age (years, M (SD)): 37.3 (11.0)
Gender (% male): 43 %
Extract: LI 160
Dosage: 300 mg, 3 times a day
Comparator: fluoxetine, placebo






Number of participants: 241
Diagnosis: MDD (DSM), clinical rating scale for depression,
MDD (ICD)
Severity: moderate
Age (years, M (SD)): 48.3 (12.7) SJW; 49.5 (13.8) sertraline
Gender (% male): SJW 21 %; sertraline 31 %
Extract: STW3
Dosage: 612 mg/day/12 weeks
Comparator: sertraline






Number of participants: 388
Diagnosis: MDD (DSM), clinical rating scale for depression,
MDD (ICD)
Severity: moderate
Age (years, M (SD)): SJW 50.8 (12.1); citalopram 49.3 (10.7);
placebo 49.4 (12.7)
Gender (% male): SJW 34 %, citalopram 35 %, placebo 27 %
Extract: STW3-VI
Dosage: 900 mg/day/6 weeks
Comparator: citalopram, placebo





Number of participants: 338
Diagnosis: MDD (DSM), clinical rating scale for depression
Severity: not reported
Age (years, M (SD)): SJW 43.1 (13.5); sertraline 43.9 (13.9);
placebo 40.1 (12.2)
Gender (% male): SJW 35 %; sertraline 33 %; placebo 34 %
Extract: LI 160
Dosage: 300 mg/3 times a day/8 weeks
Comparator: sertraline, placebo






Number of participants: 108
Diagnosis: MDD (DSM), clinical rating scale for depression
Severity: not reported
Age (years, M (SD)): 53.0 (7.5) SJW; 53.5 (10.3) placebo
Gender (% male): SJW 42 %; placebo 32 %
Extract: LI 160
Dosage: 300 mg/3 times a day/6 weeks
Comparator: placebo





Number of participants: 102
Diagnosis: clinical rating scale for depression, MDD (ICD)
Severity: moderate
Age (years, M (SD)): SJW 43.8 (13.4); maprotiline 47.6 (10.9)
Gender (% male): SJW 25 %; maprotiline 31 %
Extract: LI 160
Dosage: 300 mg/3 times a day/4 weeks
Comparator: maprotiline





Number of participants: 228
Diagnosis: MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): SJW 68.4; fluoxetine 69.1
Gender (% male): 13 %
Extract: LoHyp-57
Dosage: 400 mg/two times a day/6 weeks
Comparator: fluoxetine
Follow-up time: 6 weeks
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Number of participants: 72
Diagnosis: MDD (DSM), clinical rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): SJW 48 (11); placebo 49 (10)
Gender (% male): SJW 30 %; placebo 37 %
Extract: WS 5572
Dosage: 300 mg/3 times a day/6 weeks
Comparator: placebo






Number of participants: 332
Diagnosis: MDD (DSM), clinical rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): SJW 600 mg 46.3 (11.5); SJW 1200 mg
46.1 (10.7); placebo 46.9 (11.8)
Gender (% male): SJW 600 mg 44 %; SJW 1200 mg 34 %;
placebo 31 %
Extract: WS 5570
Dosage: 600 or 1200 mg/day/6 weeks
Comparator: placebo






Number of participants: 570
Diagnosis: MDD (DSM), clinical rating scale for depression,
MDD (ICD)
Severity: mild
Age (years, M (SD)): 47.5 (10.7); placebo 47.4 (11.8)
Gender (% male): SJW 27 %; placebo 24 %
Extract: WS 5570
Dosage: 300 mg/3 times a day/26 weeks
Comparator: placebo






Number of participants: 196
Diagnosis: MDD (DSM), clinical rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): SJW WS 5572 47.3 (11.8); SJW WS 5573
48.7 (11.8); placebo 51.0 (12.7)
Gender (% male): SJW WS 5572 18 %; SJW WS 5573 14 %;
placebo 29 %
Extract: WS 5572; WS 5573
Dosage: 3 × 300 mg/day/6 weeks
Comparator: placebo





Number of participants: 375
Diagnosis: MDD (DSM), clinical rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): SJW 40.2 (11.7); placebo 41.2 (11.4)
Gender (% male): SJW 24 %; placebo 23 %
Extract: WS 5570
Dosage: 300 mg/3 times a day/6 weeks
Comparator: placebo







Number of participants: 348
Diagnosis: MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): 19–94 (range)
Gender (% male): 26 %
Extract: hypericin
Dosage: 0.17 mg, 0.33 mg, or 1 mg/day (divided into 3
doses)/6 weeks





Number of participants: 170
Diagnosis: clinical rating scale for depression, other
diagnosis, ISFC and WHO criteria
Severity: not reported
Age (years, M (SD)): SJW 67 (2.7); Deanxit 68 (2.8);
psychotherapy 68 (3.0); placebo 67 (2.5)
Gender (% male): 50 %
Extract: NA
Dosage: 300 mg/3 times a day/12 weeks
Comparator: Deanxit 10.5 mg/daily, cognitive therapy,
suggestion therapy, supportive therapy and rational emotive
therapy/twice per week, placebo (oryzanol 20 mg)/3 times a
day





Number of participants: 201
Diagnosis: clinical rating scale for depression, MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): SJW 47.0 (13.1); placebo 46.6 (13.8)
Gender (% male): 17 %
Extract: LI 160
Dosage: 300 g/2 times a day/8 weeks
Comparator: placebo





Number of participants: 248
Diagnosis: MDD (DSM)
Severity: mild-moderate
Age (years, M (SD)): NA
Gender (% male): NA
Extract: LI 160
Dosage: 300 mg/3 times a day/12 weeks
Comparator: placebo





Number of participants: 66
Diagnosis: clinical rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): 40.5 (10.7)
Gender (% male): 17 %
Extract: NA
Dosage: 300 mg/3 times a day/8 weeks
Comparator: fluoxetine, placebo





Number of participants: 40
Diagnosis: clinical rating scale for depression, other
diagnosis, diagnosed depression, method unspecified
Severity: mild-moderate
Age (years, M (SD)): SJW 29.8 (6.2); placebo 30 (16.6)
Gender (% male): SJW 50 %; placebo 45 %
Extract: NA
Dosage: 300 mcg/3 times a day/6 weeks
Comparator: nortriptyline 75–100 mg, imipramine 100–
150 mg, amitriptyline 100–150 mg/daily, placebo/daily
Follow-up time: 6 weeks
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Number of participants: 263
Diagnosis: clinical rating scale
for depression, MDD (ICD)
Severity: not reported
Age (years, M (SD)): 47 (12)
Gender (% male): 25 %
Extract: STEI 300
Dosage: 350 mg/3 times day/8 weeks
Comparator: imipramine, placebo





Number of participants: 225
Diagnosis: clinical rating scale
for depression, MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): SJW 33.89
(10.884); placebo 36.29 (12.478)
Gender (% male): SJW 23 %; placebo 21 %
Extract: NA
Dosage: 300 mg/3 times a day/6 weeks
Comparator: placebo






Number of participants: 162
Diagnosis: clinical rating scale for
depression, MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): SJW 47
(32–59.25, 25–75 % range);
placebo 39 (30–59.25, 25–75 % range)
Gender (% male): SJW 28 %; placebo 38 %
Extract: ZE117
Dosage: 250 mg/2 times a day/6 weeks
Comparator: placebo





Number of participants: 240
Diagnosis: clinical rating scale
for depression, MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): SJW 46 (19);
fluoxetine 47 (17)
Gender (% male): SJW 29 %;
fluoxetine 41 %
Extract: Ze 117
Dosage: 250 mg/2 times a day/6 weeks
Comparator: fluoxetine






Number of participants: 200
Diagnosis: MDD (DSM), clinical
rating scale for depression
Severity: Mild-moderate
Age (years, M (SD)): SJW 41.4
(12.5); placebo 43.3 (13.7)
Gender (% male): SJW 35 %;
placebo 37 %
Extract: NA
Dosage: 300 mg/a day/8 weeks
Comparator: placebo





Number of participants: 251
Diagnosis: MDD (DSM), clinical
rating scale for depression
Severity: moderate-severe
Age (years, M (SD)): SJW 49.0
(11.0); Paroxetine 45.5 (11.5)
Gender (% male): SJW 30 %;
paroxetine 32 %
Extract: WS 5570
Dosage: 300 mg–600 mg/3 time a day/6 weeks
Comparator: paroxetine





Number of participants: 140
Diagnosis: MDD (DSM), clinical
rating scale for depression, MDD (ICD)
Severity: not reported
Age (years, M (SD)): SJW 46.4 (12.5);
placebo 43.3 (12.6)
Gender (% male): SJW 30 %; placebo 36 %
Extract: STW 3-VI
Dosage: 900 mg/day/6 weeks
Comparator: placebo






Number of participants: 140
Diagnosis: MDD (DSM), clinical
rating scale for depression
Severity: mild-moderate
Age (years, M (SD)): 47
Gender (% male): 19 %
Extract: D-0496 (hypericin)
Dosage: 250 mg/twice a day/6 weeks
Comparator: placebo






Number of participants: 209
Diagnosis: MDD (ICD)
Severity: not reported
Age (years, M (SD)): SJW 48.8
(12.0); imipramine 50.1 (11.8)
Gender (% male): SJW 27 %;
imipramine 25 %
Extract: LI 160
Dosage: 3 × 600 mg/day/6 weeks
Comparator: imipramine
Follow-up time: 6 weeks
Apaydin et al. Systematic Reviews  (2016) 5:148 Page 11 of 25
were limited and inadequate for the assessment of rare
adverse events which lowered the quality of evidence.
SJW vs. antidepressants
a. Comparative efficacy. The included studies showed
the efficacy of SJW for depression symptoms was com-
parable to antidepressant medication, with SJW being
neither inferior nor superior. We found no systematic
differences in the rate of treatment responders (RR 1.01;
CI 0.90, 1.14; 17 RCTs; I2 52 %; N = 2776; Fig. 5) com-
paring SJW and standard antidepressant medication. Pa-
tients also did not have different depression scale scores
(SMD −0.03; CI −0.21, 0.15; 14 RCTs; I2 74 %; N = 2248;
Fig. 6) comparing the two treatment approaches but the
heterogeneity was substantial (74 %). The effects for the
treatment responder rate and depression scale scores
remained stable when analyses were limited to RCTs
that had reported a power calculation and that had suffi-
cient statistical power to detect differences between
treatments (treatment responders: RR 0.98; CI 0.80, 1.19;
5 RCTs; I2 59 %; scale scores: SMD 0.03; CI −0.75, 0.84;
4 RCTs; I2 91 %). Pooled estimates were similar when
excluding poor quality studies; however, the study qual-
ity of this subset of studies was limited with mostly fair
quality studies, which lowered our confidence in the evi-
dence assessment.
Patients who received SJW did not experience remis-
sion from depression at statistically significantly lower or
higher rates than patients who received antidepressants
(RR 1.17; CI 0.84, 1.62; 7 RCTs; I2 29 %; N = 787; Fig. 7).
However, studies reporting on remission were limited
due to study quality and the statistical power to detect
differences between interventions was unclear. The qual-
ity of evidence was downgraded accordingly.
Only one RCT reported on depression relapse and
quality of life and effect estimates were not replicated in
another, independent study resulting in a very low qual-
ity of evidence rating (Table 3).
All but one identified comparative study compared
SJW to antidepressant medication. One study compared
SJW and psychotherapy and no replication was identi-
fied in the literature. Meta-regressions comparing SSRIs,
tricyclic antidepressants, and other antidepressants did
not suggest a systematic association with the treatment
effect estimates (outcome treatment responders p =
0.505; outcome depression scale scores p = 0.210; out-
come remission p = 0.654). The majority of studies tested
SJW compared to SSRIs. Subgroup analyses did not





Number of participants: 165
Diagnosis: MDD (DSM), clinical
rating scale for depression
Severity: Mild-moderate
Age (years, M (SD)): SJW 42
(range: 20–64); Amitriptyline 38
(range: 24–65)
Gender (% male): SJW 16 %;
Amitriptyline 23 %
Extract: LI 160
Dosage: 300 mg/3 times a day/6 weeks
Comparator: Amitriptyline





Number of participants: 97
Diagnosis: clinical rating scale
for depression, MDD (ICD)
Severity: Not reported
Age (years, M (SD)): 44.7 (10.9)
SJW; 41.6 (12.5) placebo
Gender (% male): SJW 31 %;
placebo 37 %
Extract: psychotonin forte
Dosage: 100–120 mg/2 times a day/6 weeks
Comparator: placebo






Number of participants: 324
Diagnosis: clinical rating scale
for depression, MDD (ICD)
Severity: mild-moderate
Age (years, M (SD)): SJW 46.5
(12.7); imipramine 45.4 (12.8)
Gender (% male): SJW 29 %;
imipramine 29 %
Extract: Ze 117
Dosage: 250 mg/2 times a day/6 weeks
Comparator: imipramine
Follow-up time: 6 weeks





Number of participants: 90
Diagnosis: MDD (DSM), clinical
rating scale for depression
Severity: not reported
Age (years, M (SD)): SJW 40.9
(11.6); sertraline 39.1 (10.2)
Gender (% male): SJW 36 %;
sertraline 42 %
Extract: NR
Dosage: 1–2 300 mg/3 times a day/12 weeks
Comparator: sertraline
Follow-up time: 12 weeks
NA not applicable, NR not reported
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Table 3 Summary of findings and quality of evidence table
Outcome Study design: number of studies,
number of participants
Findings: direction and magnitude of effect GRADE
Comparison: SJW vs. placebo
Depression, number of treatment responders 18 RCTs, N = 2922 RR 1.53 (1.19, 1.97), favors SJW Moderatea
Depression scale score 16 RCTs, N = 2888 SMD 0.49 (0.23, 0.74), favors SJW Moderatea
Depression remission 9 RCTs, N = 1419 RR 1.69 (0.63, 4.55), n.s. Lowa,b
Depression relapse 1 RCT, N = 426 RR 0.70 (0.49, 1.02), n.s. Very
lowa,b
Quality of life—mental 2 RCTs, N = 358 SMD 0.48 (0.24, 0.73), favors SJW Lowb
Quality of life—physical 2 RCTs, N = 358 SMD 0.28 (−1.03, 0.47), n.s. Very
lowa,b
Number of patients with adverse events 13 RCTs, N = 2600 OR 0.83 (0.62, 1.13), n.s. Moderateb
Serious adverse events 6 RCTs, N = 1358 OR 0.26 (0.04, 1.23), n.s. Moderatea
Gastrointestinal/metabolic/nutritional adverse
events
16 RCTs, N = 2490 OR 1.06 (0.83, 1.41), n.s. Lowa,b
Neurologic/nervous system adverse events 14 RCTs, N = 2404 OR 1.56 (1.08, 3.32) SJW more AE Lowa,b
Skin/musculoskeletal adverse events 10 RCTs, N = 1978 OR 1.47 (0.98, 2.21), n.s. Very
lowa,b
Photosensitivity 4 RCTs, N = 1054 OR 1.10 (0.36, 3.56), n.s. Lowa,b
Respiratory/infectious adverse events 7 RCTs, N = 1081 OR 1.48 (0.95, 2.33), n.s. Lowa,b
Other organ system (eye, ear, liver, renal,
reproductive) adverse events
5 RCTs, N = 1054 OR 1.87 (1.08, 3.32), SJW more AE Lowa,b
Cardiovascular adverse events 4 RCTs, N = 759 OR 6.81 (0.92, 304.08), n.s. Very
lowa,b,d
Psychiatric adverse events 3 RCTs, N = 608 OR 1.61 (0.34, 10.21), n.s. Very
lowa,b,d
Sexual dysfunction adverse events 2 RCTs, N = 428 OR 1.92 (0.94, 4.00), n.s. Very
lowa,b,d
Comparison: SJW vs. antidepressant
Depression, number of treatment responders 17 RCTs, N = 2776 RR 1.01 (0.90, 1.14), n.s. Moderateb
Depression scale score 14 RCTs, N = 2248 SMD 0.03 (−0.15, 0.21), n.s. Moderateb
Depression remission 7 RCTs, N = 787 RR 1.17 (0.84, 1.62), n.s. Lowb
Depression relapse 1 RCT, N = 241 RR 4.17 (0.47, 33.33), n.s. Very
lowa,b
Quality of life—mental 1 RCT, N = 216 SMD −0.11 (−0.15, 0.38), n.s. Very
lowa,b
Quality of life—physical 1 RCT, N = 153 SMD 0.35 (0.01, 0.70), favors SJW Very
lowa,b
Number of patients with adverse events 11 RCTs, N = 1946 OR 0.67 (0.56, 0.81), favors SJW Moderatea
Serious adverse events 4 RCTs, N = 805 OR 0.62 (0.05, 5.46) n.s. Lowa,b
Gastrointestinal/metabolic/nutritional adverse
events
15 RCTs, N = 2491 OR 0.43 (0.34, 0.55) favors SJW Lowa,b
Neurologic/nervous system adverse events 15 RCTs, N = 2492 OR 0.29 (0.24, 0.36) favors SJW Lowa,b
Skin/musculoskeletal adverse events 10 RCTs, N = 1587 OR 1.18 (0.79, 1.78) n.s. Lowa,b
Respiratory/infectious adverse events 2 RCTs, N = 352 OR 1.25 (0.70, 2.25) n.s. Very
lowa,b
Other organ system (eye, ear, liver, renal,
reproductive) adverse events
4 RCTs, N = 761 OR 0.85 (0.52, 1.38), n.s. Lowa,b
Cardiovascular adverse events 5 RCTs, N = 750 OR 0.55 (0.26, 1.16), n.s. Lowa,b
Psychiatric adverse events 4 RCTs, N = 552 OR 0.41 (0.19, 0.87) favors SJW Very
lowa,b
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show differences between SJW and SSRIs (outcome
treatment responders RR 1.02; CI 0.87, 1.20; 11
RCTs; I2 52 %; outcome depression scale scores
SMD 0.10; CI −0.08, 0.27; 10 RCTs; I2 59 %; out-
come remission RR 1.09; CI 0.76, 1.56; 6 RCTs; I2
27 %), but the heterogeneity was much lower than
the analyses of SJW vs. all antidepressants, indicating
that the type of antidepressants may be a source of
differences between study results.
b. Comparative safety. In the included RCTs compar-
ing SJW to standard antidepressant medications, there
was evidence that more patients taking antidepressants
experienced adverse events (OR 0.67; CI 0.56, 0.81; 11
RCTs; Table 3). Specifically, SJW was associated with
fewer adverse events in the gastrointestinal (OR 0.43; CI
0.34, 0.55; 15 RCTs, Table 3) and neurologic (OR 0.29;
CI 0.24, 0.36; 15 RCTs, Table 3) organ systems. Adverse
events involving psychiatric or sexual functioning
were also lower in patients treated with SJW, but
only a small number of studies reported on these
symptoms. Serious adverse events did not differ sta-
tistically significantly between the treatment ap-
proaches (OR 0.62; CI 0.05, 5.46; 4 RCTs, Table 3),
but this result was also based on a small number of
studies.
Subgroup analyses for different types of antidepres-
sant medication were hindered by the small number
of RCTs testing a specific antidepressant and report-
ing on specific adverse events. In the largest group
of antidepressants used in studies, SSRIs, subgroup
results were similar to the main analysis, but the dif-
ference in the number of participants with adverse
events was not statistically significantly different (OR
0.81; CI 0.63, 1.04; 7 RCTs). There were fewer
serious adverse events in the SJW group but the dif-
ference was not statistically significant (OR 0.62; CI
0.05, 5.46; 3 RCTs) across three RCTs. In studies on
tricyclic antidepressants, more participants experi-
enced adverse events than compared to SJW (OR
0.43; CI 0.25, 0.72; 3 RCTs) but only three studies
contributed to this analysis. One RCT in this sub-
group that reported on serious adverse events re-
ported the absence of events in both groups.
The rigor of adverse event assessments and the
reporting of recorded events varied greatly across
studies. Comparative analyses were potentially limited
due to the lack of statistical power to show differ-
ences in individual rare events. In addition, the RCTs
only addressed a limited range of potential adverse
events. Consequently, the quality of evidence was
downgraded, in particular when sensitivity analyses
excluding poor quality studies could not be performed
or suggested different effect estimates.
Other results
We also investigated the comparative effects of the
different extracts used in included studies. We found
only one study that compared two different stan-
dardized extracts and three studies that compared
different dosages, none of which found statistically
significant differences between treatment arms. A
meta-regression across studies did not indicate sys-
tematic differences in outcomes depending on the
extract used (outcome treatment responders p =
0.347; outcome depression scale scores p = 0.127;
outcome remission p = 0.371). An extract of 0.3 %
hypericin and 1 to 4 % hyperforin was the tested ex-
tract with the largest number of RCTs (8 studies).
Table 3 Summary of findings and quality of evidence table (Continued)
Sexual dysfunction adverse events 2 RCTs, N = 301 OR 0.51 (0.30, 0.88) favors SJW Lowa,b
Effect of depression severity




















Quality of evidence was downgraded (by 1 or by 2, depending on the severity) for the following
aInconsistency (heterogeneity, direction of effects; no replication)
bStudy limitations (no good quality study; effect not present when excluding poor quality studies; studies not designed or not powered to assess outcome)
cIndirectness (no head-to-head trials, effect based on indirect comparison)
dImprecision (wide confidence interval)
SJW St. John’s wort, n.s. not statistically significantly different, AE adverse event
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All but one RCT evaluated SJW as monotherapy and
only one RCT provided data on SJW as adjunctive
therapy precluding further analyses. Although we
searched the international literature without language
restriction, 51 % of included studies were conducted
in Germany. Meta-regressions found mixed results:
no indication that effect sizes differ by study in the
outcome number of responders (p = 0.078), number
of patients with adverse events (p = 0.95), or the out-
come depression remission (p = 0.058), but German
Fig. 2 SJW vs. placebo, treatment responder rate; RE random effects, RR relative risk, SJW St. John’s wort
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studies reported a stronger effect of SJW than non-
German studies for the continuous outcome change in de-
pression rating scales (p = 0.012).
Review question 2: Is there a difference in effect, depending
on the type of MDD (i.e. mild, moderate, severe)?
We examined the variation in efficacy and safety of
SJW by MDD severity to answer our second review
question. Of the identified studies, 12 included patients
with either mild or moderate depression. Three studies
are limited to patients with moderate depression alone.
No study was identified that examined patients with
Fig. 3 SJW vs. placebo, depression scale standardized mean differences; RE random effects, SJW St. John’s wort, SMD standardized
mean differences
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mild depression alone. Finally, only one study was iden-
tified that focused exclusively on patients with severe
depression.
SJW vs. placebo
A meta-regression aiming to identify an association be-
tween the depression severity and the size of the treat-
ment effect of SJW compared to placebo did not
indicate a systematic difference in any of the outcomes
that had sufficient study numbers to enable analyses
(outcome treatment responders p = 0.798; outcome de-
pression scale scores p = 0.365; outcome remission p =
0.159). We determined that the quality of evidence that
suggested that there is no difference in SJW effectiveness
depending on depression severity as very low (Table 3).
This was due to the fact that the results were based on
Fig. 4 SJW vs. placebo, number of patients in remission; RE random effects, RR relative risk, SJW St. John’s wort
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an indirect comparison across studies (a meta-regression),
the majority of samples were in mixed patient samples of
combined mild or moderate-severe depression, and the ab-
sence of data on patients with severe depression which lim-
ited the range of depression severity that was analyzed.
We also found no indication that the number of pa-
tients with adverse events differed significantly between
depression severity subgroups (p = 0.480); however, all
limitations to the evidence base outlined in the effective-
ness analyses apply equally to this analysis.
Fig. 5 SJW vs. antidepressants, treatment responder rate; RE random effects, RR relative risk, SJW St. John’s wort
Apaydin et al. Systematic Reviews  (2016) 5:148 Page 18 of 25
The effect of SJW among only patients with mild-
moderate depression was similar to main analyses for
treatment responders (RR 1.45; CI 1.09, 1.92; 10 RCTs;
I2 71 %) and scale score (SMD 0.51; CI 0.20, 0.82; 9
RCTs; I2 81 %) outcomes. Only three studies examined
the effect of SJW on moderate depression against
placebo, and all three showed significant effects in terms
of treatment responder rate and depression scale scores
[22, 37, 43]. These effects were nonsignificant in the
pooled analyses of these three studies for treatment re-
sponders (RR 2.50; CI 0.16, 33.33; 3 RCTs; I2 96 %) and
severity (SMD 0.86; CI 1.11, 2.83; 3 RCTs; I2 96 %), and
Fig. 6 St. John’s wort vs. antidepressants, depression scale standardized mean differences; RE random effects, SJW St. John’s wort, SMD
standardized mean differences
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we detected high heterogeneity between the trials. We
identified no study reporting on patients with severe de-
pression comparing SJW with placebo.
Analyses could only be performed for selected outcomes
due to the small number of studies in some subgroups. In
addition, the large majority of studies were in samples of
combined mild and moderate depression, hence poten-
tially differential effects of SJW for patients with mild,
moderate, or severe depression could not be determined.
SJW vs. antidepressants
We did not identify differences in effectiveness between
the interventions in the mild and moderate subgroups
analyzing the outcome number of treatment responders
(RR 1; CI 0.77, 1.30; 8 RCTs; I2 63 %), depression scale
scores (SMD 0.16; CI 0.33, 0.65; 5 RCTs; I2 76 %), or pa-
tients in remission (RR 0.89; CI 0.57, 1.41; 4 RCTs; I2 0 %).
The results for the number of participants with ad-
verse events showed similar results to the main adverse
Fig. 7 SJW vs. antidepressants, number of patients in remission; RE random effects, RR relative risk, SJW St. John’s wort
Apaydin et al. Systematic Reviews  (2016) 5:148 Page 20 of 25
event analysis, with studies reporting fewer patients with
adverse events in the SJW intervention group compared
to antidepressant medication (OR 0.65; CI 0.56, 0.77; 7
RCTs).
In the subgroup of moderate depression severity, there
were no differences between interventions for the out-
come number of treatment responders (RR 0.98; CI 0.88,
1.09; 4 RCTs; I2 0 %) or depression scale scores (SMD
0.13; CI −0.13, 0.45; 3 RCTs; I2 4 %). One RCT in severe
depression [44] reported no statistically significant differ-
ence between the SJW extract LI 160 and imipramine
for the number of treatment responders (RR 0.79; CI
0.45, 1.37; 1 RCT) or mean depression scale scores
(SMD −0.17; CI −0.44, 0.11; 1 RCT).
Analyses could only be performed for selected out-
comes due to the small number of studies in the sub-
groups. In addition, studies were primarily in samples of
combined mild and moderate depression severity and
only one study with patient with severe depression was
identified. Consequently, whether the comparison be-
tween SJW and antidepressants differs systematically by
depression severity could not be determined.
Discussion
The available evidence suggests that SJW extracts are ef-
fective in treating patients with mild and moderate
MDD compared to placebo and comparable to antide-
pressants. Observed adverse events were fewer than
compared to antidepressants, however, adverse event as-
sessments were limited.
The existing evidence base indicates that SJW is a
herbal alternative to antidepressant medication with
fewer adverse events without compromising effective-
ness in symptom improvement in mild and moderate
depression. Improvements in depression symptoms were
shown for treatment response rates and on standard
clinical scales. Translating the shown effect size esti-
mates into clinically meaningful units, the average re-
sponse rate, i.e. participants showing a marked response
to treatment, was 56 % for SJW compared to a response
rate in patients treated with a placebo of 35 %. The
mean standardized effect size estimate seen across stud-
ies is equivalent to a 3-point reduction on the HAMD
scale compared to placebo treatment. Our confidence in
the summary effect was downgraded to moderate quality
of evidence due to heterogeneity across studies. While
studies were consistently favoring SJW over placebo, the
size of the treatment effect estimates varied substantially
across included studies. Despite a large number of meta-
regressions and subgroup analyses, we were unable to
identify significant sources of differences between stud-
ies that could explain the heterogeneity shown in the
pooled results. Therefore, findings have to be interpreted
with caution. Future research may provide more insights
for which patient group SJW is particularly effective or
which intervention characteristics are associated with
larger treatment effects.
Our review also addressed the outcome remission
using study authors’ definitions, which usually corre-
sponded to a HAMD score of less than seven or eight
and indications that no further treatment was required.
While remission rates were lower among participants
using SJW compared to a placebo, these results were not
statistically significant and the quality of evidence was
low due to mixed study quality and differences in results
across studies. The average proportion of patients in re-
mission was 38 % in SJW treatment groups and 27 % in
placebo groups.
The evidence base indicated that SJW was not less (or
more) effective than antidepressants in treating major
depressive disorder in patients with mild and moderate
depression. Treatment response rates and depression se-
verity did not differ between patients administered SJW
and antidepressants, including studies that were expli-
citly designed to detect statistically significant differences
between the treatment groups. Remission rates were also
not significantly different but given the lack of effect
shown in placebo trials and the limited quality of the
identified studies this result has to be interpreted with
caution. Remission rates were low in SJW as well as
antidepressant arms (average 38 and 33 %, respectively);
of note, the follow-up times in the included studies were
relatively short (range 4–12 weeks).
Patients taking SJW were not more likely to experi-
ence adverse events than patients receiving a placebo
across all assessed adverse events. Serious adverse event
rates did not differ between the groups, but users of
SJW experienced more adverse events related to the ner-
vous system or to eye, ear, liver, renal, and reproductive
organ systems. Conversely, SJW treatment was associ-
ated with fewer adverse events overall than antidepres-
sants, and specifically for adverse events related to the
gastrointestinal and nervous systems. Serious adverse
events did not differ significantly between the two treat-
ment groups, but only a few studies reported on adverse
events and the identified RCTs were not designed to ad-
dress rare adverse events. The quality of evidence of ad-
verse event effect estimates was downgraded given that
the rigor of assessments varied and the studies were not
designed to detect rare events. Although all but one
study reported on adverse events, the assessment and
reporting varied considerably. Studies varied in particu-
lar on which adverse events they reported on; the pres-
ence or absence of serious adverse events was only
addressed in a small proportion of studies. SJW has been
linked to specific rare events such as hypertensive crisis
and induction of mania, but the adverse event reporting
in identified studies was often generic and concentrated
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on gastrointestinal aspects and tolerability. In order to
advance our knowledge of the effects of SJW, empirical
evidence of the presence and the absence of adverse
events is critical and should be addressed in future
research.
The presented analyses did not indicate that the effect
of SJW on major depression differs by depression sever-
ity. However, the existing research is based on patients
with mild or moderate depression. The mixed depres-
sion severity samples and the absence of data on patients
with severe depression hindered any meaningful analysis.
To date, the effects of SJW in patients with severe de-
pression are not known. Clinicians need to be aware that
results of our review may not extrapolate to include all
patients with MDD.
As for clinical practice recommendations, there are
demonstrated positive findings. Nonetheless, some con-
cerns remain. Our review was in particular unable to
dismiss concerns of rare adverse events that have been
linked to SJW due to the lack of trials addressing these
harms [7]. Some existing practice guidelines, such as the
UK Guidelines for Depression in Adults [51], advise not
to prescribe SJW because of uncertainty about appropri-
ate doses, persistence of effect, variation in the nature of
preparations and potential serious interactions with
other drugs (including oral contraceptives, anticoagu-
lants, and anticonvulsants). A 2012 review advised
against using SJW with oral contraceptives, as well as
immunosuppressants or cardiovascular drugs and a re-
view looking specifically at warfarin found interactions
between SJW and this anticoagulant [52, 53]. Further-
more, a review of popular herbal preparations found
SJW interacted with more medications than any of the
other herbs and dietary supplements [54]. Post-
marketing surveillance of spontaneous adverse drug re-
actions indicated that SJW produced a similar adverse
event profile to fluoxetine, with mild and severe adverse
events more common with SJW while life-threatening
events were more common with fluoxetine but still oc-
curred [55]. While reports of rare adverse events cannot
be dismissed based on RCT data, it is noteworthy that
SJW appears to have fewer adverse events than anti-
depressant medication in the reported comparative
analyses.
A further relevant point for practice is that the re-
search findings are based on SJW monotherapy. Existing
research used the herb SJW as an alternative treatment
to antidepressant medication, not as an additional treat-
ment option that can be added to standard treatment.
This aspect is in particular relevant to patients with se-
vere depression. Post-marketing surveillance in Australia
found that, though SJW was not often given with an
SSRI, there was a high proportion of adverse effects
when this occurred, including a report of life-
threatening serotonin syndrome [55]. While concerns
about potential drug interactions will have prompted re-
searchers to not provide patients with SJW in addition
to standard antidepressant medication, we also did not
identify studies that evaluated the effect of SJW treat-
ment adjunctive to psychotherapy.
Too few studies compared the different extracts and
dosages of SJW to draw meaningful conclusions about
the differential effects of various types and amounts of
the herb. There was similarly very low quality of evi-
dence for the differential effect of SJW as an adjunctive
therapy compared to it as a monotherapy due to a lack
of trials on the comparison. The results of this review
are comparable to the conclusions of a previous
Cochrane review of SJW for major depression by Linde
et al., in 2008, which found that SJW extracts are super-
ior to placebo for MDD, are similarly effective as stand-
ard antidepressants, and have fewer side effects than
standard antidepressants [6]. Our review included all but
one of the 29 studies from that review [17–27, 29, 30,
34, 35, 37, 39–50]. One of the trials could not be re-
trieved [56]. Our review added an additional seven stud-
ies [16, 28, 31–33, 36, 38] that had been more recently
published or included comparative effectiveness data.
The proportion of non-German studies was higher in
our study pool with half of included studies reporting on
patients recruited in other countries. The findings of a
more recent systematic review of pharmacological treat-
ments for depressive disorders in primary care [5] were
consistent with the previous review, in that hypericum
extracts showed similar efficacy and better acceptability
than antidepressants and are effective for the treatment
of acute depression, though effects when compared to
placebo were modest.
This review has several strengths: an a priori research
design, a comprehensive search of electronic databases
without language restriction, duplicate study selection
and abstraction of study information, detailed risk of
bias assessments, and comprehensive quality of evidence
evaluations used to formulate review conclusions. How-
ever, some limitations are worth noting. First, we did not
contact individual study authors; results reported in the
review are based on published data. Some of the in-
cluded studies were of poor quality, primarily due to lack
of ITT or poor follow-up. The depression improvements
associated with SJW were seen in the analyses of the
number of treatment responders, as well as mean de-
pression scale scores; however, both treatment effect es-
timates showed heterogeneity. A large number of
subgroup and sensitivity analyses did not identify sys-
tematic sources of differences between studies, and het-
erogeneity remains as a limitation of the SJW evidence.
Adverse event evidence is limited because the rigor of
adverse event assessments varied greatly; comparative
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analyses were potentially limited due to the lack of stat-
istical power to show differences in individual rare
events; and, RCTs only assessed a limited range of po-
tential adverse events.
Future research in this area should include more head-
to-head trials between specific extracts and dosages of
SJW to evaluate their comparative effectiveness. While
potential risks of drug interactions hinders research of
SJW as an adjunctive treatment, research on SJW con-
comitant to psychotherapy are also missing. Future re-
search studies should clearly report on the presence and
absence of adverse events, in particular rare events
linked to SJW. As quality of life is greatly affected by
MDD, it would be important to see more studies of de-
pression treatment include this measure. Adverse events
should be systematically assessed to determine concrete
evidence of the presence and absence of adverse events.
Conclusions
Our systematic review showed that SJW given as mono-
therapy for mild and moderate depression is superior to
placebo in improving symptoms and not significantly
different from antidepressant medication; however, there
was evidence of substantial heterogeneity between stud-
ies and we were unable to identify systematic sources of
differences between studies. In addition, there is a lack
of research on applications of SJW in severe depression.
SJW adverse events reported in included RCTs were
comparable to placebo and fewer compared to anti-
depressant medication; however, adverse event assess-
ments were limited and inadequate for rare events
affecting our confidence in this conclusion.
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